128 related articles for article (PubMed ID: 35420647)
1. Urticaria 12 Days After COVID-19 mRNA Booster Vaccination.
Wolfson AR; Freeman EE; Blumenthal KG
JAMA; 2022 May; 327(17):1702-1703. PubMed ID: 35420647
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
Di Filippo M; Ferraro D; Ragonese P; Prosperini L; Maniscalco GT; Gallo A; Cavalla P; Lorefice L; Nociti V; Di Sabatino E; Clerico M; Guaschino C; Radaelli M; Fantozzi R; Buttari F; Laroni A; Gajofatto A; Calabrese M; Malucchi S; Paolicelli D; De Luca G; Tomassini V; Lanzillo R; Moccia M; Solaro C; Cocco E; Gasperini C; Tortorella C;
J Neurol; 2024 Jan; 271(1):24-31. PubMed ID: 37922069
[TBL] [Abstract][Full Text] [Related]
3. Development of immediate and chronic spontaneous urticaria following mRNA COVID-19 vaccination: Tolerability of revaccination and immunological study.
Teo RXW; Leung BPL; Thong BY; Tan JWL; Chan GYL; Lim XR
Ann Acad Med Singap; 2024 Jan; 53(1):57-59. PubMed ID: 38920217
[No Abstract] [Full Text] [Related]
4. Safety and Adverse Events Among Long-term Care Residents Receiving a Third COVID-19 mRNA Vaccine Booster Dose in Quebec.
Zhang XS; Moreau A; Cruz-Santiago D; Langevin S; Nguyen QD
JAMA Netw Open; 2022 Jul; 5(7):e2223401. PubMed ID: 35862047
[TBL] [Abstract][Full Text] [Related]
5. Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination.
Triwatcharikorn J; Puaratana-Arunkon T; Punyaratabandhu P; Mongkolpathumrat P; Palapinyo S; Buranapraditkul S; Rerknimitr P; Klaewsongkram J
Clin Exp Dermatol; 2022 Apr; 47(4):735-738. PubMed ID: 34609771
[TBL] [Abstract][Full Text] [Related]
6. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination.
Pitlick MM; Joshi AY; Gonzalez-Estrada A; Chiarella SE
Allergy Asthma Proc; 2022 Jan; 43(1):40-43. PubMed ID: 34983709
[No Abstract] [Full Text] [Related]
7. Urticarial vasculitis triggered by SARS-CoV-2 vaccine (mRNA vaccine).
Daldoul M; Korbi M; Bellalah A; Ben Fadhel N; Belhadjali H; Zili J
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):e743-e744. PubMed ID: 35604050
[No Abstract] [Full Text] [Related]
8. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
[TBL] [Abstract][Full Text] [Related]
9. Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease.
Connolly CM; Frey S; Chiang TP; Teles M; Alejo JL; Albayda J; Shah AA; Werbel WA; Segev DL; Christopher-Stine L; Paik JJ
Rheumatology (Oxford); 2022 Oct; 61(10):e302-e304. PubMed ID: 35583259
[No Abstract] [Full Text] [Related]
10. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
[TBL] [Abstract][Full Text] [Related]
11. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
[TBL] [Abstract][Full Text] [Related]
12. Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.
Wang M; Wen W; Zhou M; Wang C; Feng ZH
Am J Cardiol; 2022 Mar; 167():155-157. PubMed ID: 35063268
[No Abstract] [Full Text] [Related]
13. Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign.
Mattiuzzi C; Lippi G
Eur J Public Health; 2022 Apr; 32(2):328-330. PubMed ID: 34978571
[TBL] [Abstract][Full Text] [Related]
14. Vitiligo worsened following the second dose of mRNA SARS-CoV-2 vaccine.
Caroppo F; Deotto ML; Tartaglia J; Belloni Fortina A
Dermatol Ther; 2022 Jun; 35(6):e15434. PubMed ID: 35266259
[No Abstract] [Full Text] [Related]
15. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
Choi A; Koch M; Wu K; Chu L; Ma L; Hill A; Nunna N; Huang W; Oestreicher J; Colpitts T; Bennett H; Legault H; Paila Y; Nestorova B; Ding B; Montefiori D; Pajon R; Miller JM; Leav B; Carfi A; McPhee R; Edwards DK
Nat Med; 2021 Nov; 27(11):2025-2031. PubMed ID: 34526698
[TBL] [Abstract][Full Text] [Related]
16. [Delayed acute urticaria after the third vaccine against SARS-CoV-2].
Gimeno Castillo J; Garrapiz Borderías I
Semergen; 2022 Sep; 48(6):437-438. PubMed ID: 35527184
[No Abstract] [Full Text] [Related]
17. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
Greenberg RS; Ruddy JA; Boyarsky BJ; Werbel WA; Garonzik-Wang JM; Segev DL; Imus PH
BMC Cancer; 2021 Dec; 21(1):1354. PubMed ID: 34961488
[TBL] [Abstract][Full Text] [Related]
18. Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination.
Maeda M; Isawa T; Tada N
Circ J; 2022 Mar; 86(4):724. PubMed ID: 34866122
[No Abstract] [Full Text] [Related]
19. Response to Comment on D'Addio et al. Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes. Diabetes 2022;71:1800-1806.
D'Addio F; Fiorina P
Diabetes; 2022 Sep; 71(9):e14. PubMed ID: 35984961
[No Abstract] [Full Text] [Related]
20. Equivalent humoral and cellular immune response but different side effect rates following SARS-CoV-2 vaccination in peritoneal and haemodialysis patients using messenger RNA vaccines.
Stumpf J; Klimova A; Mauer R; Steglich A; Gembardt F; Martin H; Glombig G; Frank K; Tonn T; Hugo C
Nephrol Dial Transplant; 2022 Mar; 37(4):796-798. PubMed ID: 34791446
[No Abstract] [Full Text] [Related]
[Next] [New Search]
